An NIMH-funded study showed that incorporating depression treatment into care for chronic health conditions improved well-being for both patients and their families.
A new study, funded in part by the National Institute of Mental Health, showed that a new medication derived from ketamine is safe and acceptable for use in humans, setting the stage for clinical trials testing it for hard-to-treat mental disorders like severe depression.
NIMH-supported research suggests AI tools built on smartphone data may struggle to predict clinical outcomes like depression in large and diverse groups of people.
In a new neuroimaging study funded by the National Institute of Mental Health, researchers used repetitive transcranial magnetic stimulation to target regions deep in the brain to help reduce depression symptoms.
An NIMH-funded research consortium has produced the largest and most advanced multidimensional maps of gene regulation networks in the brains of people with and without mental disorders.
• 75th Anniversary
Decades of NIMH-supported basic research led to a pioneering treatment for postpartum depression and continues to power exciting advances in women's mental health care.
Results from a large clinical trial funded by the National Institutes of Health show that an intervention for anxiety provided to pregnant women living in Pakistan significantly reduced the likelihood of the women developing moderate-to-severe anxiety, depression, or both six weeks after birth.
This clinical trial found that MST is equally effective at reducing depression symptoms as ECT, but with fewer side effects.
• 75th Anniversary
NIMH supported science and NIMH researchers helped pave the way for the development of ketamine—a groundbreaking treatment that has improved the lives of those who are impacted by treatment-resistant depression.
In this NIMH-funded study, researchers examined how trauma gets passed from one generation to the next.
New NIMH-funded research tracked population-level rates of postpartum depression among new mothers before, during, and after pregnancy.
An NIMH-supported study suggests that a brief self-association training program can extend the effects of a single ketamine infusion by shifting people’s negative self-beliefs.
In a recent study supported by the National Institute of Mental Health, researchers examined the impact of a family-based intervention on suicide risk in youth and found risk-reduction benefits up to 10 years later.
NIMH-supported researchers have found an online mindfulness-based cognitive behavioral therapy—called Mindful Mood Balance—is effective at reducing residual depressive symptoms and at reducing suicidal ideation in those who experience these symptoms.
TMS can only directly stimulate the outermost layer of the brain, but NIMH researchers have found that mapping a person’s brain architecture may make it possible to guide TMS to deep brain targets.
A recent NIMH-supported study investigated whether deep brain stimulation could be personalized for individuals with treatment-resistant depression.
NIMH-supported researchers investigated suicide risk among women in the year before and year after giving birth.
NIMH is working to meet the urgent need for rapid-acting suicide prevention interventions by supporting research investigating the feasibility and safety of treatment protocols that have the potential to quickly reduce severe suicide risk in youth and adults.
A new study conducted by researchers at NIMH suggests that differences in the expression of gene transcripts – readouts copied from DNA that help maintain and build our cells – may hold the key to understanding how mental disorders with shared genetic risk factors result in different patterns of onset, symptoms, course of illness, and treatment responses.
In a project funded by the NIMH Small Business Technology Transfer program, researchers are investigating whether mobile technology can be used to create a passive monitoring system that can predict teens’ depressive symptoms and improve the quality of their care.
Carlos Zarate Jr., M.D., chief of the Experimental Therapeutics and Pathophysiology Branch within the NIMH Intramural Research Program, has been elected to the National Academy of Medicine.
Researchers investigating how temperament shapes adult life-course outcomes have found that behavioral inhibition in infancy predicts a reserved, introverted personality at age 26 and for some, a risk of internalizing psychopathology such as anxiety and depression.
An innovative NIMH-funded trial shows that a receptor involved in the brain’s reward system may be a viable target for treating anhedonia (or lack of pleasure), a key symptom of several mood and anxiety disorders.
The use of right unilateral ultrabrief pulse (RUL-UB) electroconvulsive therapy (ECT) in combination with the antidepressant venlafaxine to treat depression in elderly patients is well tolerated and results in minimal neurocognitive side effects, according to a new NIH-funded study published in the American Journal of Geriatric Psychiatry.
For many adults who have a mental disorder, symptoms were present—but often not recognized or addressed—in childhood and adolescence. Early treatment can help prevent more severe, lasting impairment or disability as a child grows up.
NIH-funded research uses machine learning algorithm to predict individual response to a commonly-prescribed antidepressant.
A single, low-dose ketamine infusion was relatively free of side effects for patients with treatment-resistant depression.
Researchers have uncovered sex-based differences in the development of the hippocampus and amygdala—brain areas that have been implicated in the biology of several mental disorders that impact males and females differently.
Mental health research center directors emerged from a recent meeting with a renewed commitment to help each other achieve their common mission – to transform care of children, adolescents and adults with severe psychiatric disorders.
A study conducted by researchers at several universities, hospitals, and the National Institute of Mental Health (NIMH) found that the Netflix show “13 Reasons Why” was associated with a 28.9% increase in suicide rates among U.S. youth ages 10-17 in the month (April 2017) following the shows release, after accounting for ongoing trends in suicide rates.
The National Institutes of Health invites students ages 16 to 18 years old to participate in the “Speaking Up About Mental Health!” essay contest to explore ways to address the stigma and social barriers that adolescents from racial and ethnic minority populations may face when seeking mental health treatment.
Researchers have identified ketamine-induced brain-related changes that are responsible for maintaining the remission of behaviors related to depression in mice — findings that may help researchers develop interventions that promote lasting remission of depression in humans.
FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.
Researchers have identified changes in brain connectivity and brain activity during rest and reward anticipation in children with anhedonia, a condition where people lose interest and pleasure in activities they used to enjoy.
A research team found nearly one-third of youth ages 10 to 12 years screened positive for suicide risk in emergency department settings, including those seeking help for physical concerns only.
A new study looking at interactions among sleep, energy, activity level, and mood suggests that instability in activity and sleep systems could lead to mood changes. The findings suggest new targets for depression treatment.
Researchers funded by the National Institutes of Health have shown that a therapy-based treatment for disruptive behavioral disorders can be adapted and used as an effective treatment option for early childhood depression.
On May 3, 2018, join NIMH for a Twitter chat on teen depression with experts Dr. Argyris Stringaris and Dr. Ken Towbin.
Depression, schizophrenia and autism spectrum disorder share some of the same patterns of suspect gene expression – molecular signatures.
On February 20, 2018, join NIMH for a Twitter chat on Seasonal Affective Disorder with expert Dr. Matthew Rudorfer.
Using a molecular method likely to become widely adopted by the field, researchers have discovered brain circuitry essential for alertness – and for brain states more generally.
Brain gene expression associated with depression differed markedly between men and women. Such divergent “transcriptional signatures” may signal divergent underlying illness processes requiring sex-specific treatments.
This November 2016 RDoC webinar highlights the role of fear and anxiety in disorders such as phobias and depression.
A streamlined behavioral therapy delivered in a pediatrics practice offered much greater benefit to youth with anxiety and depression than a more standard referral to mental health care with follow-up in a clinical trial comparing the two approaches.
NIMH grantee Karl Deisseroth, M.D., Ph.D., of Stanford University, has been awarded one of science’s most generous prizes. A German foundation presented the inventor of technologies that are transforming neuroscience with its 4 million euros Fresenius Prize.
Brain scans reveal that fluctuations in estrogen can trigger atypical functioning in a key brain memory circuit in women with a common version of a gene. Since working memory function is often disturbed in mental disorders, such gene-hormone interactions are suspect mechanisms that may confer risk.
Scientists have discovered 15 genome sites – the first ever – linked to depression in people of European ancestry. But – in a twist – the researchers didn’t have to sequence anyone’s genes! Instead, they analyzed data already shared by people who had purchased their own genetic profiles via an online service and elected to participate in its research option.
An individualized program of follow-up treatment with electroconvulsive therapy (ECT) combined with an antidepressant was effective in preventing relapse in patients 60 years and older who had had a successful initial course of treatment for severe depression.
A live Twitter chat discussing African American men’s mental health.
A chemical byproduct, or metabolite, created as the body breaks down likely holds the secret to its rapid antidepressant action .
On March 17, 2016, NIMH hosts a Facebook Q&A on electroconvulsive therapy with expert Dr. Sarah Lisanby.
Is mobile mental health research the next frontier for smartphones? Based on Dr. Patricia Areán’s pioneering BRIGHTEN study, research via smartphone app is already a reality.
View the archived webinars with NIMH experts and grantees, which focus on training, research, and methodology
A new video about postpartum depression marks the launch of a mental health education collaboration by two NIH Institutes and one of the nation’s largest African-American women’s organizations.
NIMH and NCI host a Twitter chat on how patients and caregivers, across all ages, can deal with the psychological impact of cancer.
Risk genes for different mental disorders work through same pathways
